35 patents currently held
46 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2027. from the record
Of the 46 now held by other companies, 37 name PH Health Limited as their current owner, and 9 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
23
Ending by 2030
Jun 2027
Next term end
21
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2028 · High confidence
Also notable
Ends Sep 2029 · High confidence
Also notable
Ends Jan 2029 · High confidence
Also notable
Ends May 2028 · High confidence
Also notable
Ends Nov 2029 · High confidence
Also notable
Ends Jun 2029 · High confidence
Also notable
Ends Jan 2031 · High confidence
Also notable
Ends Jun 2027 · High confidence
Method for Supporting Vaginal Cuff
US 7,901,346
Cited by 131 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Apparatus for Treating Stress and Urge Incontinence
US 8,195,296
Cited by 71 later US patents, top 10% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Sustained release formulations of nalbuphine
US 8,771,732
Cited by 23 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Surgical Implants and Related Methods
US 7,722,527
The most cited patent in this portfolio, cited by 1,907 later US patents, top 1% of utility patents granted in 2010 in our data. Protection runs to 2028.
Multi-Leveled Transgluteal Tension-Free Levatorplasty for Treatment of Rectocele
US 8,585,577
Cited by 57 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Oligonucleotide Duplexes Comprising DNA-Like and RNA-Like Nucleotides and Uses Thereof
US 9,090,649
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
Methods and Systems for Treatment of Prolapse
US 8,535,217
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2031.
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
US 9,789,103
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Dec 2029 · High confidence
Cited by 100 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Also notable
Ends Dec 2029 · High confidence
Cited by 68 later US patents, top 10% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Also notable
Ends Jan 2035 · Low confidence
Cited by 25 later US patents, top 25% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
now held by PH Health Limited
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 7 to 28, 2027 · next Jan 7
- 1 fee due Mar 1, 2027The maintenance fee for Implant Device Release Agents and Methods of Using Same (US 9,120,249) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Apparatus and Method for Repairing Vaginal Reconstruction (US 9,149,351) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 2 fees due May 14 to 17, 2027 · next May 14
Recent changes
- 7 terms have ended since Aug 21, 2026
What they patent
The largest of its 21 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,553,863 | Ultrapure 4-Methylpyrazole In force · High confidence | In force | High confidence | |
| US 8,808,737 | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment In force · High confidence | In force | High confidence | |
| US 9,789,103 | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment In force · High confidence | In force | High confidence | |
| US 11,389,443 | Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment In force · High confidence | In force | High confidence | |
| US 9,186,374 | Vitamin B12 Nasal Spray and Method of Use In force · Medium confidence | In force | Medium confidence | |
| US 7,722,527 | Surgical Implants and Related Methods In force · High confidence | In force | High confidence | |
| US 7,901,346 | Method for Supporting Vaginal Cuff In force · High confidence | In force | High confidence | |
| US 8,394,812 | Sustained Release Formulations of Nalbuphine In force · High confidence | In force | High confidence | |
| US 8,771,732 | Sustained release formulations of nalbuphine In force · High confidence | In force | High confidence | |
| US 9,090,649 | Oligonucleotide Duplexes Comprising DNA-Like and RNA-Like Nucleotides and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 35: 46 patents in force now held by others · 61 patents ended · 20 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.